FDA Decision Due Thursday on a Two-Drug HIV Pill Designed to Simplify Complex Daily Regimens

The FDA faces an August 27 target date on Gilead’s bictegravir and lenacapavir tablet for adults already virally suppressed on HIV therapy.

Have A Referral?